Quantisnow Logo
Dashboard

SEC Form SC 13G filed by Biolase Inc.

$BIOL
Medical/Dental Instruments
Health Care
Get the next $BIOL alert in real time by email
SC 13G 1 biol20230131G.txt 2023 JAN 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Biolase, Inc (Name of Issuer) Common (Title of Class of Securities) 090911405 (CUSIP Number) January 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: |X| Rule 13d-1(b) | | Rule 13d-1(c) | | Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 090911405 Schedule 13G Page 2 of 5 ___________________________________________________________________________ 1.Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only). Perkins Capital Managment, Inc. 41-1501962 ___________________________________________________________________________ 2.Check the Appropriate Box if a Member of a Group (See Instructions) (a) / / (b) / / ___________________________________________________________________________ 3.SEC Use Only ___________________________________________________________________________ 4.Citizenship or Place of Organization A Minnesota Corporation ___________________________________________________________________________ Number of 5.Sole Voting Power Shares Bene- 2,503,285 _________________________________________________________ ficially owned 6.Shared Voting Power 0 by Each _________________________________________________________ 7.Sole Dispositive Power 3,288,581 Reporting _________________________________________________________ 8.Shared Dispositive Power Person With: 0 ___________________________________________________________________________ 9.Aggregate Amount Beneficially Owned by Each Reporting Person 3,288,581 ____________________________________________________________________________ 10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ____________________________________________________________________________ 11.Percent of Class Represented by Amount in Row 9 11.9% ____________________________________________________________________________ 12.Type of Reporting Person (See Instructions) IA ____________________________________________________________________________ Item 1. (a)Name of Issuer: Biolase, Inc. (b)Address of Issuer's Principal Executive Offices 27042 Towne Centre Drive, Suite 270, Lake Forest, CA 92610 Item 2. (a)Name of Person Filing Perkins Capital Management, Inc. (b)Address of Principal Business Office or, if none, Residence 730 Lake St E Wayzata, MN 55391 (c)Citizenship A Minnesota Corporation (d)Title of Class of Securities Common (e)CUSIP Number 053734208 Item 3. If this statement is filed pursuant to ss240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) | | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) | | Bank as defined in section 3(s)(6) of the Act (15 U.S.C. 78c). (c) | | Insurance Company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) | | Investment Company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) |X| An investment adviser in accordance with s240.13d-1(b)(1)(ii)(E); (f) | | An employee benefit plan or endowment fund in accordance with s240.13d-1(b)(1)(ii)(F); (g) | | A parent holding company or control person in accordance with s240.13d-1(b)(ii)(G); (h) | | A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) | | A church plan that is excluded from the definition of an investment company under section 3c(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) | | Group, in accordance with s240.13d-1(b)(1)(ii)(J). Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 3,288,581 (includes 2,760,481 common equivalents and 528,100 warrants exercisable within 60 days) (b) Percent of Class: 11.9% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote: 2,503,285 (ii) Shared power to vote or to direct the vote: 0 (iii) Sole power to dispose or to direct the disposition of: 3,288,581 (includes 2,760,481 common equivalents and 528,100 warrants exercisable within 60 days) (iv) Shared power to dispose or to direct the disposition of: 0 Instruction: For computations regarding securities which represent a right to acquire an underlying security see s240.13d(1). Item 5. Ownership of Five Percent or Less of a Class If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following / /. Item 6. Ownership of More than Five Percent on Behalf of Another Person. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company Item 8. Identification and Classification of Members of the Group Item 9. Notice of Dissolution of Group Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief,the securities referred to above were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 8, 2023 ______________________________ (Date) /s/ Richard C. Perkins ______________________________ (Signature) Richard C. Perkins President ______________________________ (Name/Title)
Get the next $BIOL alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$BIOL

DatePrice TargetRatingAnalyst
More analyst ratings

$BIOL
 Press Releases

Fastest customizable press release news feed in the world

See more

  • BIOLASE Voluntarily Initiates Chapter 11 Proceedings

    LAKE FOREST, CA / ACCESSWIRE / October 1, 2024 / BIOLASE, Inc. (NASDAQ:BIOL) (the "Company"), a global leader in dental lasers, today announced that the Company and its direct domestic subsidiaries have voluntarily initiated Chapter 11 proceedings (the "Bankruptcy Petitions") in the United States Bankruptcy Court for the District of Delaware (the "Court"). BIOLASE will seek Court approval to continue operating during the proceedings and remains focused on providing its customers with its award-winning dental lasers and customer service.The Company also announced today that it is pursuing a sale process under Section 363 of the Bankruptcy Code in conjunction with the filing. To this end, BIOL

    $BIOL
    Medical/Dental Instruments
    Health Care

  • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    $BIOL
    Medical/Dental Instruments
    Health Care

  • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

$BIOL
 Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$BIOL
 Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$BIOL
 SEC Filings

See more

$BIOL
 Leadership Updates

Live Leadership Updates

See more

  • Strateos Appoints Alexander K. Arrow as Chief Financial Officer and Expands Team

    Juliet M. Moritz appointed Vice President, Project Management Office Strateos, Inc., a pioneer in the development of remote access laboratories and lab automation software for life science research, today announced the appointment of Alexander K. Arrow, MD, CFA, as Chief Financial Officer. Dr. Arrow will join the Executive Leadership team and play a key role in leading the company's business and finance strategy focused on growth and new investments. The company has also named Juliet M. Moritz, MPH, Vice President, Project Management Office, reflecting the significant demand by large pharmaceutical companies and contract research organizations for deployment of Strateos Lodestar™ Software.

    $BIOL
    Medical/Dental Instruments
    Health Care

  • BIOLASE NAMES DR. RUSSELL MORROW AS CHIEF DENTAL OFFICER

    Dr. Morrow brings extensive clinical, dental and DSO experience to help expand laser adoption globally LAKE FOREST, Calif., Oct. 13, 2022 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ:BIOL), a global leader in dental lasers, today announced the appointment of Russell Morrow, D.D.S. as Chief Dental Officer ("CDO"), effective November 1, 2022. Dr. Samuel Low, who has served as Chief Dental Officer since 2016, will be taking on a new role as Vice President, Clinical Strategic Alliances, where he will focus on building partnerships and growth with Dental Service Organizations (DSOs), universities and government institutions.

    $BIOL
    Medical/Dental Instruments
    Health Care

  • BIOLASE Expands Core Capabilities As It Appoints Three New Board Members With Significant Dental Experience

    FOOTHILL RANCH, Calif., Aug. 16, 2021 /PRNewswire/ -- Demonstrating a deep commitment to expanding the core capabilities and diversity of its Board of Directors, BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced it has appointed three new board members to its Board of Directors (the "Board"), effective immediately. Drs. Kathleen T. O'Loughlin, Carol Gomez Summerhays, and Martha Somerman join a Board that has been instrumental in establishing and implementing the Company's business plan, which has demonstrated significant growth over the past several quarters.

    $BIOL
    Medical/Dental Instruments
    Health Care

$BIOL
 Financials

Live finance-specific insights

See more

  • BIOLASE Reports 2024 Second Quarter Results; Achieves 40% Gross Margin as Global Consumable Sales Strengthen

    LAKE FOREST, CA / ACCESSWIRE / August 8, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the second quarter ended June 30, 2024."We experienced another strong quarter in consumable revenue, recording our second-highest mark ever and achieving over 600 recurring subscriptions," commented John Beaver, President and Chief Executive Officer of BIOLASE. "This success translates to over $2 million in scheduled shipments over the next twelve months. Our gross margin increased to 40%, up from 33% in the first quarter of 2024, due to cost reduction efforts implemented earlier in the year. Despite ongoing revenue challenges due to highe

    $BIOL
    Medical/Dental Instruments
    Health Care

  • SWK Holdings Highlights Recent Achievements and Provides Portfolio Update

    DALLAS, TX / ACCESSWIRE / July 17, 2024 / SWK Holdings Corporation (NASDAQ:SWKH) ("SWK" or the "Company"), a life science-focused specialty finance company catering to small and mid-sized commercial-stage companies, today provided a corporate progress update as well as a summary of the achievements of its borrower portfolio companies."During the second quarter we advanced capital to two existing borrowers and are working towards an additional closing in the next month," said SWK President and CEO Jody Staggs."Importantly, several of our borrower partners took advantage of the strong capital markets to raise equity or other forms of non-dilutive financing. We also repurchased $1 million of st

    $BIOL
    $BTCY
    $DERM
    $ELUT
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Biotechnology: Biological Products (No Diagnostic Substances)

  • Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability

    Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and SuccessLAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024.First Quarter Financial HighlightsGenerated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialistsThird strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptionsGross margin was re

    $BIOL
    Medical/Dental Instruments
    Health Care

$BIOL
 Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more